Johnson & Johnson (JNJ)
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Johnson & Johnson Gets FDA Approval for Treatment, Makes Acquisition of Up to $1.7 Billion
The FDA has approved Rybrevant plus Lazcluze in the U.S. for the treatment of patients with non-small cell lung cancer.
J&J to acquire V-Wave for up to $1.7 billion in play for heart failure device
Johnson & Johnson JNJ said Tuesday it has agreed to acquire V-Wave Ltd., a privately held company developing treatments for patients with heart failure, for $600 million upfront and potential extra payments of up to $1.1 billion. V-Wave will become part of Johnson & Johnson Medtech. The deal will help J&J “accelerate its shift into high-growth and high-opportunity markets and will deepen its relationships with structural interventional cardiologists and heart failure specialists,” the company said in a statement. V-Wave's cardiovascular implant technology targets heart failure with reduced ejection fraction, or HFrEF....
J&J to buy medical device maker V-Wave in up to $1.1 bln deal
Johnson & Johnson said on Tuesday it would buy medical device maker V-Wave in a deal potentially worth up to $1.1 billion, marking the latest acquisition to bolster its devices unit.
US FDA approves J&J's combination therapy for type of lung cancer
The U.S. Food and Drug Administration on Tuesday approved Johnson & Johnson's chemotherapy-free combination therapy for patients with a type of non-small cell lung cancer.
Johnson & Johnson wins first FDA approval for chemotherapy-free lung cancer treatment
Johnson & Johnson JNJ, +0.15% said Tuesday the U.S. Food and Drug Administration has approved a combination treatment for a type of lung cancer that's the first chemotherapy-free regimen. The FDA has approved the combination of Rybrevant plus Lazcluze for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer, or NSCLC, with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test, the company said in a statement.
Why Is Johnson & Johnson (JNJ) Up 2.4% Since Last Earnings Report?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
The Highest Quality Dividend-Growth Healthcare Stocks
Quality Snapshots evaluate dividend-growth companies based on five quality factors including financial performance, resilience and dividend safety. This healthcare sector overview identifies 26 top quality stocks in the sector. Johnson & Johnson and Zoetis discussed as high-quality, fairly valued healthcare stocks with very different yields and growth rates.
Prediction: Johnson & Johnson's Dividend Payouts Will Increase in 2025
24/7 Wall St. Insights Stocks that consistently raise their dividends offer investors huge total return potential.
J&J to disclose support for $6.5 billion talc settlement
Johnson & Johnson is preparing to unveil widespread support in coming days for a $6.48 billion offer to settle tens of thousands of legal actions alleging its Baby Powder and other talc products caused cancer, two people familiar with the matter said.
Exclusive: J&J near disclosing support for talc settlement, sources say
Johnson & Johnson is preparing to unveil widespread support in coming days for a $6.48 billion offer to settle tens of thousands of legal actions alleging its Baby Powder and other talc products caused cancer, two people familiar with the matter said.
3 Blue-Chip Stocks to Buy on the Dip: August 2024
Blue-chip stocks are commanding attention from investors looking for stability and reliability amidst a fluctuating market. Typically, these stock market stalwarts are known for their solid financials, long histories of profitability and consistent records of dividend payments.
